Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

283 ARTÍCULOS , VIENDO DEL 241 AL 255

Role of progranulin as a biomarker for Alzheimer's disease

Sleegers K, Brouwers N, Van Broeckhoven C.

Biomark Med. 2010 Feb;4(1):37-50. doi: 10.2217/bmm.09.82.

Blood-based biomarkers of Alzheimer's disease: challenging but feasible

Thambisetty M, Lovestone S.

Biomark Med. 2010 Feb;4(1):65-79. doi: 10.2217/bmm.09.84.

Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials

Siemers E, DeMattos RB, May PC, Dean RA.

Biomark Med. 2010 Feb;4(1):81-9. doi: 10.2217/bmm.09.85.

Biochemical markers in Alzheimer's disease clinical trials

Zetterberg H, Mattsson N, Shaw LM, Blennow K.

Biomark Med. 2010 Feb;4(1):91-8. doi: 10.2217/bmm.09.80.

Correlating familial Alzheimer's disease gene mutations with clinical phenotype

Ryan NS, Rossor MN.

Biomark Med. 2010 Feb;4(1):99-112. doi: 10.2217/bmm.09.92.

Biomarkers in translational research of Alzheimer's disease

Tarawneh R, Holtzman DM.

Neuropharmacology. 2010 Sep-Oct;59(4-5):310-22. doi: 10.1016/j.neuropharm.2010.04.006. Epub 2010 Apr 13.

Cerebrospinal fluid proteins in the diagnosis of Alzheimer's disease

Papaliagkas VT, Tsolaki M, Anogianakis G.

Recent Pat CNS Drug Discov. 2010 Jun;5(2):172-8. doi: 10.2174/157488910791213194.

Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design

van Rossum IA, Vos S, Handels R, Visser PJ.

J Alzheimers Dis. 2010;20(3):881-91. doi: 10.3233/JAD-2010-091606.

Should olfactory dysfunction be used as a biomarker of Alzheimer's disease?

Wesson DW, Wilson DA, Nixon RA.

Expert Rev Neurother. 2010 May;10(5):633-5. doi: 10.1586/ern.10.33.

Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease

Frisardi V, Solfrizzi V, Seripa D, Capurso C, Santamato A, Sancarlo D, Vendemiale G, Pilotto A, Panza F.

Ageing Res Rev. 2010 Oct;9(4):399-417. doi: 10.1016/j.arr.2010.04.007. Epub 2010 May 2.

Integrating ADNI results into Alzheimer's disease drug development programs

Cummings JL.

Neurobiol Aging. 2010 Aug;31(8):1481-92. doi: 10.1016/j.neurobiolaging.2010.03.016. Epub 2010 May 5.

Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects

Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter WZ, Weiner MW, Jack CR Jr, Jagust W, Toga AW, Lee VM, Shaw LM; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2010 May;6(3):230-8. doi: 10.1016/j.jalz.2010.03.008.

Geriatric medicine, Japanese Alzheimer's disease neuroimaging initiative and biomarker development

Arai H, Okamura N, Furukawa K, Kudo Y.

Tohoku J Exp Med. 2010 Jun;221(2):87-95. doi: 10.1620/tjem.221.87.

What's next?

Coleman PD.

Neurobiol Aging. 2010 Aug;31(8):1493. doi: 10.1016/j.neurobiolaging.2010.05.005. Epub 2010 Jun 11.

Plasma beta-amyloid as potential biomarker of Alzheimer disease: possibility of diagnostic tool for Alzheimer disease

Takeda S, Sato N, Rakugi H, Morishita R.

Mol Biosyst. 2010 Oct;6(10):1760-6. doi: 10.1039/c003148h. Epub 2010 Jun 21.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias